Well, lets get rid of some of the 'assumptions' you've been suggesting, for a start.
CDC published COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020 in Morbidity and Mortality Weekly Report on Aug. 14 last, and laid out some facts. Link to the article & tables: https://www.cdc.gov/mmwr/volumes/69/wr/mm6932e2.htm
and here are a few relevant extracts:
- As of July 29, 2020, a total of 570 MIS-C patients with onset dates from March 2 to July 18, 2020, had been reported from 40 state health departments, the District of Columbia, and New York City;
- A total of 203 (35.6%) of those patients had a clinical course consistent with previously published MIS-C reports, characterized predominantly by shock, cardiac dysfunction, abdominal pain, and markedly elevated inflammatory markers, and almost all had positive SARS-CoV-2 test results. The remaining 367 (64.4%) of MIS-C patients had manifestations that appeared to overlap with acute COVID-19 (2–4), had a less severe clinical course, or had features of Kawasaki disease;
- Latent class analysis identified three classes of patients, each of which had significantly different illness manifestations related to some of the key indicator variables. Class 1 represented 203 (35.6%) patients who had the highest number of involved organ systems. Within this group, 99 (48.8%) had involvement of six or more organ systems; those most commonly affected were cardiovascular (100.0%) and gastrointestinal (97.5%). Compared with the other classes, patients in class 1 had significantly higher prevalences of abdominal pain, shock, myocarditis, lymphopenia, markedly elevated C-reactive protein (produced in the liver in response to inflammation), ferritin (an acute-phase reactant), troponin (a protein whose presence in the blood indicates possible cardiac damage), brain natriuretic peptide (BNP), or proBNP (indicative of heart failure) (p<0.01) . Almost all class 1 patients (98.0%) had positive SARS-CoV-2 serology test results with or without positive SARS-CoV-2 RT-PCR test results. These cases closely resembled MIS-C without overlap with acute COVID-19 or Kawasaki disease.
- Within the Class 1 group, reported serum laboratory values showed (presumably on hospitalisation) among other values e.g. platelets, ferritin:
- BNP, peak (pg/mL) 53 patients, median value of 1,321, IQR of (414–2,528)
- CRP, peak (mg/L) 166 patients, median value of 21, IQR of (14–29)
So, as @eieio said, the two children referred to in the Pediatrics article were clearly severe cases (outliers) - with BNP's of 4465 and 6528, and CRPs of 147 and 231 respectively, post SOC and MIS-C treatment and immediately prior to Remestemcel-l treatment. There seems no doubt that the progression of their disease was unacceptable to clinical staff, and far outside the norm for MIS-C patients. To suggest that any conclusion should be drawn simply from the fully-disclosed involvement of MSB consultants in the therapy is disingenuous, to say the least.
- Forums
- ASX - By Stock
- MSB
- Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-106
-
- There are more pages in this discussion • 318 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.18 |
Change
0.018(1.50%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.15 | $1.20 | $1.15 | $1.183M | 1.011M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 64675 | $1.18 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 37319 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
21 | 200252 | 1.185 |
13 | 40944 | 1.180 |
11 | 106494 | 1.175 |
11 | 136676 | 1.170 |
6 | 55721 | 1.165 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 41020 | 2 |
1.195 | 66345 | 11 |
1.200 | 144652 | 17 |
1.205 | 106279 | 10 |
1.210 | 122829 | 9 |
Last trade - 10.55am 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online